GE Healthcare Enters Personalized Rx Space with $5M Investment in CardioDx
May 19, 2010
GE Healthcare Enters Personalized Rx Space with $5M Investment in CardioDx
The infusion of funding into CardioDx represents the first investment of GE's $250 million Healthymagination Fund, which was launched in October and plans to invest in "highly promising" young companies developing life sciences tools, diagnostics, or healthcare information technologies.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- CardioDx Says $58M Financing Will Support Commercial Expansion Following Medicare Coverage Win
August 29, 2012 / Pharmacogenomics Reporter - CardioDx Continues Adoption, Coverage Push for Corus CAD
September 26, 2012 / Pharmacogenomics Reporter - CardioDx Hopeful Palmetto Coverage Decision for Corus CAD Test Will Encourage Physician Adoption
August 15, 2012 / Pharmacogenomics Reporter - GE's Clarient to be Key Beneficiary of $1B Bid to Bolster Molecular Dx Presence in Oncology
September 21, 2011 / Pharmacogenomics Reporter - CardioDx to Use $60M Funding Round to Make Clinical Utility Case for Corus CAD
May 18, 2011 / Pharmacogenomics Reporter